Holen Sie sich die Stockscreener-App
3.08
8.07%
0.23
Vorhandelsmarkt:
3.10
0.02
+0.65%
Schlusskurs vom Vortag:
$2.85
Offen:
$2.86
24-Stunden-Volumen:
882.47K
Relative Volume:
0.47
Marktkapitalisierung:
$330.85M
Einnahmen:
$42.51M
Nettoeinkommen (Verlust:
$-116.49M
KGV:
-2.75
EPS:
-1.12
Netto-Cashflow:
$-120.82M
1W Leistung:
+17.56%
1M Leistung:
-0.65%
6M Leistung:
-66.77%
1J Leistung:
-71.82%
1-Tages-Spanne:
$2.86
$3.10
1-Wochen-Bereich:
$2.60
$3.10
52-Wochen-Spanne:
$2.585
$13.01
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie TNGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
3.08 | 330.85M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Analysts Set Expectations for TNGX FY2025 Earnings - MarketBeat
Tango Therapeutics' Stock Sinks To US$2.62, But Insiders Sold Even Lower - Simply Wall St
Barclays PLC Has $972,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics Highlights Breakthroughs in Cancer Treatment - TipRanks
Jane Street Group LLC Has $391,000 Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Rating of "Buy" by Analysts - MarketBeat
Franklin Resources Inc. Has $126,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Geode Capital Management LLC Has $10.54 Million Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Barclays PLC Raises Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
State Street Corp Purchases 489,949 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Purchased by State Street Corp - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $580,000 Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
The Manufacturers Life Insurance Company Cuts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts - Investing.com India
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts By Investing.com - Investing.com South Africa
TNGX Stock Hits 52-Week Low at $2.7 Amid Market Challenges - Investing.com UK
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Cantor Fitzgerald Reaffirms Overweight Rating for Tango Therapeutics (NASDAQ:TNGX) - Defense World
Adaptive Biotechnologies Corp (ADPT) With A Potential Upside Of More Than -193.16% - Stocks Register
Unveiling 5 Analyst Insights On Tango Therapeutics - Benzinga
Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth? - Simply Wall St
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Decreases By 21.7% - MarketBeat
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - Business Wire
Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock By Investing.com - Investing.com Canada
Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock - Investing.com
Trv Gp Iv LLC Cuts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
B. Riley Increases Earnings Estimates for Tango Therapeutics - Defense World
B. Riley Forecasts Higher Earnings for Tango Therapeutics - MarketBeat
B. Riley Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $8.00 - Defense World
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 inhibitor progress - Investing.com
Tango Therapeutics (NASDAQ:TNGX) Earns “Buy” Rating from HC Wainwright - Defense World
The Analyst Landscape: 5 Takes On Tango Therapeutics - Benzinga
B. Riley Has Lowered Expectations for Tango Therapeutics (NASDAQ:TNGX) Stock Price - MarketBeat
FY2024 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for TNGX - MarketBeat
EcoR1 Capital sells $8.4 million in Tango Therapeutics stock - Investing.com India
EcoR1 Capital sells $8.4 million in Tango Therapeutics stock By Investing.com - Investing.com Australia
Tango Therapeutics' (TNGX) Buy Rating Reiterated at HC Wainwright - MarketBeat
EcoR1 Capital, LLC Adjusts Stake in Tango Therapeutics Inc - GuruFocus.com
Wedbush Has Pessimistic Outlook of TNGX FY2024 Earnings - Defense World
Wedbush Forecasts Reduced Earnings for Tango Therapeutics - MarketBeat
Tango Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):